 |
|
UNC scientists discover 'gatekeeper' protein in blood clotting
January 30, 2006New research from the University of North Carolina at Chapel Hill School of Medicine has identified a protein that may control blood clotting by keeping blood platelets from sticking together.
Uncontrolled interactions between blood platelets such as those that occur during heart attacks and strokes contribute to these leading causes of death nationwide.
The study, which appears in the Jan. 17 edition of the Journal of Cell Biology, indicates that CIB1 binds to and keeps the platelet adhesion receptor GPIIb/IIIa in an inactive state, thus blocking platelet-to-platelet interactions in the blood.
Dr. Weiping Yuan, an assistant professor in UNC's department of pharmacology and the study's lead author, said CIB1's role was as a "gatekeeper" of GPIIb/IIIa activation. "Originally, I was a little surprised. We expected CIB1 itself to activate GPIIb/IIIa, but that is clearly not the case. CIB1 keeps GPIIb/IIIa turned off until it should be activated."
The UNC laboratory of Dr. Leslie V. Parise, professor of pharmacology and the new study's senior author, discovered the protein CIB1 in 1997. It was found inside platelets as a protein that binds to GPIIb/IIIa.
Under normal conditions, GPIIb/IIIa, found on the surface of platelets, remains in a resting, inactive state that allows normal blood flow. However, during clotting, GPIIb/IIIa becomes active, binds platelets to one another and attaches them to the blood vessel wall, thus forming a clot.
GPIIb/IIIa also is the target of several anti-coagulation drug therapies used in the clinic today, but the study suggests that knowledge of how CIB1 functions may lead to new therapeutic approaches.
The report, which used platelet precursor cells, demonstrated that decreasing the amount of CIB1 in these cells makes GPIIb/IIIa more responsive, thus more likely to mediate blood clotting. Increasing the amount of CIB1 prevented GPIIb/IIIa activation.
"Our data suggest that CIB1 may be one of the body's own natural anti-coagulants - as long as CIB1 is bound to GPIIb/IIIa, the platelet stays quiet. However, if a person doesn't have enough CIB1 or their CIB1 isn't functional, then their platelets may have the potential to be hyper-responsive and pathologically predisposed to clotting," Parise said. Additionally, the authors propose that CIB1 maintains the adhesion receptor in its inactive state by preventing the binding of another protein called talin to GPIIb/IIIa, which has been shown in other studies to be an adhesion receptor activator.
"CIB1 and talin compete for binding to the adhesion receptor; therefore, we think that as long as CIB1 is bound to the adhesion receptor, this prevents talin from binding and activating the receptor," said Dr. Tina Leisner, assistant professor of pharmacology and one of the study's primary authors.
The group now plans further study of the molecular mechanisms of the CIB1/GPIIb/IIIa interaction, which could lead to the development of new therapies in the prevention of platelet activation.
University of North Carolina School of Medicine
Dr. Weiping Yuan, an assistant professor in UNC's department of pharmacology and the study's lead author, said CIB1's role was as a "gatekeeper" of GPIIb/IIIa activation. "Originally, I was a little surprised. We expected CIB1 itself to activate GPIIb/IIIa, but that is clearly not the case. CIB1 keeps GPIIb/IIIa turned off until it should be activated."
The UNC laboratory of Dr. Leslie V. Parise, professor of pharmacology and the new study's senior author, discovered the protein CIB1 in 1997. It was found inside platelets as a protein that binds to GPIIb/IIIa.
Under normal conditions, GPIIb/IIIa, found on the surface of platelets, remains in a resting, inactive state that allows normal blood flow. However, during clotting, GPIIb/IIIa becomes active, binds platelets to one another and attaches them to the blood vessel wall, thus forming a clot.
GPIIb/IIIa also is the target of several anti-coagulation drug therapies used in the clinic today, but the study suggests that knowledge of how CIB1 functions may lead to new therapeutic approaches.
The report, which used platelet precursor cells, demonstrated that decreasing the amount of CIB1 in these cells makes GPIIb/IIIa more responsive, thus more likely to mediate blood clotting. Increasing the amount of CIB1 prevented GPIIb/IIIa activation.
"Our data suggest that CIB1 may be one of the body's own natural anti-coagulants - as long as CIB1 is bound to GPIIb/IIIa, the platelet stays quiet. However, if a person doesn't have enough CIB1 or their CIB1 isn't functional, then their platelets may have the potential to be hyper-responsive and pathologically predisposed to clotting," Parise said. Additionally, the authors propose that CIB1 maintains the adhesion receptor in its inactive state by preventing the binding of another protein called talin to GPIIb/IIIa, which has been shown in other studies to be an adhesion receptor activator.
"CIB1 and talin compete for binding to the adhesion receptor; therefore, we think that as long as CIB1 is bound to the adhesion receptor, this prevents talin from binding and activating the receptor," said Dr. Tina Leisner, assistant professor of pharmacology and one of the study's primary authors.
The group now plans further study of the molecular mechanisms of the CIB1/GPIIb/IIIa interaction, which could lead to the development of new therapies in the prevention of platelet activation.
University of North Carolina School of Medicine
Blood Clotting Current Events and Blood Clotting News RSSAlternatively spliced tissue factor identified as promising new biomarker for aggressive cancers
A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.
'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery
Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals.
Super sticky barnacle glue cures like blood clots
Barnacles are a big problem for boats. Adhering to the undersides of vessels, carpets of the crustaceans can increase fuel consumption by as much as 25%.
Liver cells grown from patients' skin cells
Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients' skin cells opening the possibility of treating a wide range of diseases that affect liver function.
New blood-thinning drug safer than rat poison
In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.
Scientists pinpoint protein link to fat storage
A protein found present in all cells in the body could help scientists better understand how we store fat.
New research confirms potential deadly nature of emerging new monkey malaria species in humans
Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection.
Pregnancy complications are a stress test for future maternal health and pregnancies
Predicting whether pregnancy complications affect long-term maternal health as well as future pregnancies is at the heart of two studies conducted by researchers in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine.
New American College of Surgeons risk calculator determines colorectal surgery risk
New research published in the June issue of the Journal of the American College of Surgeons shows that a risk calculator developed by the American College of Surgeons (ACS) can help surgeons provide patients with more detailed and accurate preoperative information about the risk of death and complications following colorectal surgery.
Gene therapy technique thwarts cancer by cutting off tumor blood supply
University of Florida researchers have come up with a new gene therapy method to disrupt cancer growth by using a synthetic protein to induce blood clotting that cuts off a tumor's blood and nutrient supply.
More Blood Clotting Current Events and Blood Clotting News Articles
|
New Blood Clotting Factors by F. Koller (Editor) | |
 |
Celox First Aid Temporary Traumatic Wound Treatment - 15g Pouch by SAMMedical CELOXTM is the newest generation of emergency hemostatic agents. Simpler to use and safer than older technologies, CELOX granules quickly control even severe arterial bleeding. Just pour it in, pack it, and apply pressure. No specific training is required. CELOX is not exothermic and won't burn the victim or caregiver. And CELOX works in hypothermic conditions and clots Heparinized blood. CELOX is safe to use for the entire body including head, neck and chest wounds. Most importantly, CELOX can be used instantly and without hesitation as a fast, safe and simple emergency treatment for serious bleeding. Average Time to Clot Whole Blood: 30.5 Seconds Average Time to Clot Heparinized Blood: 48 Seconds Controls Major Arterial Bleeding CELOXs unusual properties have been confirmed in wound... |
 |
Botanic Choice Super EPA (Pack of 4) by Botanic Choice Omega 3 EFAs (Essential Fatty Acids) are essential for healthy arteries, blood pressure already in normal range, and triglycerides. The EFAs in cold water fish oil are believed to be the reasons why Greenland Eskimos (whose diet is mainly fish) are known for having such good heart and circulatory health. Two softgels of our high potency Super EPA Omega 3 fish oil give you 2000 mg. of fish oil and 1398 mg. of other beneficial fatty acids, 360 mg. of EPA and 240 mg. of DHA |
 |
HemoClot Blood Clotting Gel, 1 oz. by Life Science Products HemoClot is an aid to stop bleeding in animals caused by minor cuts and wounds. It can be used for nail and beak trimming, tail docking, and ear cropping. Do not use in deep wounds or on burns |
 |
Understanding Hemophilia Part of the award winning public television series Healthy Body/Healthy Mind. Bleeding due to a cut or wound can be a little scary at times, especially if your child is a hemophiliac. Hemophiliacs lack specific blood proteins known as clotting factors that our bodies need to control bleeding following an injury. Fortunately, there is far more hope than ever before for these young patients. This episode features individuals with hemophilia who are successfully managing the disease in a manner that allows them to enjoy active and productive lives. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Blood STOP Hemostatic Gauze by TITLE Boxing A hemostatic gauze that contains the finest oxidized and regenerated cellulose for a natural solution to bleeding control. Generous 2" x 2" sterilized size fits perfectly in front pocket or corner bag. Cut to size and apply to cuts to help stop bleeding in seconds. When applied correctly Blood Stop helps seal wounds, speed coagulation and dissolves into a clear gel in seconds. |
 |
LONG LIFE TEAS, Organic Earl Grey Tea - 20 bags by LONG LIFE TEAS Legend has it that a Chinese Mandarin gave the recipe for this classic tea to the second British Earl Grey. One of the secrets of this blend is the fragrant oil of Bergamot, a small citrus fruit from the Mediterranean region. Suggested Use: For Herbal and black teas, bring fresh cold spring water to a rolling boil. For green tea, heat just until steam develops but not to a boil. Pour 1 cup water over each tea bag and allow to steep 3 to 5 minutes. The longer it steeps the better it tastes. Relax, enjoy the developing aroma and color, anticipate the pleasure of a perfect cup of tea. Customize your tea - because herbs extract at different rates you can increase sweetness or intensity simply by steeping longer. Decaffeinate your green and black tea naturally! Pour... |
 |
Impaired Mobility: Physical Consequences (Immobility, Preventing Complications) (Volume One) Also With: Concept Media (Primary Contributor) Describes alterations in body functions occurring with impaired mobility. Common problems such as muscular atrophy, fluid and electrolyte disturbances, disorders in blood clotting mechanisms, disuse osteoporosis, retained respiratory secretions, and urinary stasis are discussed along with their long-term negative impact on patient health. |
|
BLOOD CLOTTING FACTORS PROCEEDINGS OF THE 4TH INTERNATIONAL CONGRESS OF BIOCHEMISTRY VIENNA 1-6 SEPTEMBER 1958 VOLUME X by E. EDITED BY DEUTSCH (Author) | |
 |
Organic Hojicha Roasted Green 16 Bags by Traditional Medicinals Tea The most well known Japanese green tea variety is known as "Bancha." Hojicha is made by roasting Bancha leaves at a high temperature until they turn reddish-brown and take on a strong aromatic fragrance and roasted flavor. How does it taste? Pleasantly nutty and smoky with slightly bitter and astringent undertones. Add a slice of lemon or orange if desired. |
| © 2009 BrightSurf.com |